Brief: Marinus Pharmaceuticals Announces U.S. Commercial Launch Of Ztalmy For Seizures Associated With Cdkl5 Deficiency Disorder
28/07/2022 12:39
July 28 (Reuters) - Marinus Pharmaceuticals Inc MRNS.O :
* MARINUS PHARMACEUTICALS ANNOUNCES U.S. COMMERCIAL LAUNCH
OF
ZTALMY® (GANAXOLONE) FOR SEIZURES ASSOCIATED WITH CDKL5
DEFICIENCY DISORDER
Source text for Eikon: ID:nBw3ndfTja
Further company coverage: MRNS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Marinus Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP- Axsome Therapeutics, Ducommun, Vacasa
Brief: Immedica To Acquire Biopharmaceutical Company Marinus Pharmaceuticals
Marinus Pharmaceuticals Inc expected to post a loss of 41 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Appfolio, S&P Global, Uber
U.S. STOCKS ON THE MOVE-Newmont, Monopar Therapeutics, TKO Group